These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 38447353)

  • 1. Marginal cost per QALY estimates: What are they good for?
    Sampson C; Cookson G
    Health Policy; 2024 Apr; 142():105036. PubMed ID: 38447353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How Effective is Marginal Healthcare Expenditure? New Evidence from England for 2003/04 to 2012/13.
    Martin S; Lomas J; Claxton K; Longo F
    Appl Health Econ Health Policy; 2021 Nov; 19(6):885-903. PubMed ID: 34286470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determining the efficiency path to universal health coverage: cost-effectiveness thresholds for 174 countries based on growth in life expectancy and health expenditures.
    Pichon-Riviere A; Drummond M; Palacios A; Garcia-Marti S; Augustovski F
    Lancet Glob Health; 2023 Jun; 11(6):e833-e842. PubMed ID: 37202020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of different types of NHS expenditure on health: Marginal cost per QALY estimates for England for 2016/17.
    Martin S; Claxton K; Lomas J; Longo F
    Health Policy; 2023 Jun; 132():104800. PubMed ID: 37004415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Local health care expenditure plans and their opportunity costs.
    Karlsberg Schaffer S; Sussex J; Devlin N; Walker A
    Health Policy; 2015 Sep; 119(9):1237-44. PubMed ID: 26251323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic review of the impact of health care expenditure on health outcome measures: implications for cost-effectiveness thresholds.
    Gloria MAJ; Thavorncharoensap M; Chaikledkaew U; Youngkong S; Thakkinstian A; Chaiyakunapruk N; Ochalek J; Culyer AJ
    Expert Rev Pharmacoecon Outcomes Res; 2024 Feb; 24(2):203-215. PubMed ID: 38112068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Informing a cost-effectiveness threshold for Saudi Arabia.
    Al-Jedai AH; Lomas J; Almudaiheem HY; Al-Ruthia YSH; Alghamdi S; Awad N; Alghamdi A; Alowairdhi MA; Alabdulkarim H; Almadi M; Bunyan RF; Ochalek J
    J Med Econ; 2023; 26(1):128-138. PubMed ID: 36576804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold.
    Claxton K; Martin S; Soares M; Rice N; Spackman E; Hinde S; Devlin N; Smith PC; Sculpher M
    Health Technol Assess; 2015 Feb; 19(14):1-503, v-vi. PubMed ID: 25692211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimating a cost-effectiveness threshold for the Spanish NHS.
    Vallejo-Torres L; García-Lorenzo B; Serrano-Aguilar P
    Health Econ; 2018 Apr; 27(4):746-761. PubMed ID: 29282798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimating the Reference Incremental Cost-Effectiveness Ratio for the Australian Health System.
    Edney LC; Haji Ali Afzali H; Cheng TC; Karnon J
    Pharmacoeconomics; 2018 Feb; 36(2):239-252. PubMed ID: 29273843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimating the Marginal Productivity of the English National Health Service From 2003 to 2012.
    Lomas J; Martin S; Claxton K
    Value Health; 2019 Sep; 22(9):995-1002. PubMed ID: 31511189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reflecting the Health Opportunity Costs of Funding Decisions Within Value Frameworks: Initial Estimates and the Need for Further Research.
    Ochalek J; Lomas J
    Clin Ther; 2020 Jan; 42(1):44-59.e2. PubMed ID: 31955967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. On the role of cost-effectiveness thresholds in healthcare priority setting.
    Siverskog J; Henriksson M
    Int J Technol Assess Health Care; 2021 Jan; 37():e23. PubMed ID: 33491617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Valuing health outcomes: developing better defaults based on health opportunity costs.
    Ochalek J; Claxton K; Lomas J; Thompson KM
    Expert Rev Pharmacoecon Outcomes Res; 2021 Aug; 21(4):729-736. PubMed ID: 32954900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Supply-Side Cost-Effectiveness Thresholds: Questions for Evidence-Based Policy.
    Sampson C; Zamora B; Watson S; Cairns J; Chalkidou K; Cubi-Molla P; Devlin N; García-Lorenzo B; Hughes DA; Leech AA; Towse A
    Appl Health Econ Health Policy; 2022 Sep; 20(5):651-667. PubMed ID: 35668345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multi-gene Pharmacogenomic Testing That Includes Decision-Support Tools to Guide Medication Selection for Major Depression: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2021; 21(13):1-214. PubMed ID: 34484487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are the benefits of new health services greater than their opportunity costs?
    Edney L; Haji Ali Afzali H; Karnon J
    Aust Health Rev; 2019 Oct; 43(5):508-510. PubMed ID: 30526796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Country-Level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further Research.
    Woods B; Revill P; Sculpher M; Claxton K
    Value Health; 2016 Dec; 19(8):929-935. PubMed ID: 27987642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estimating the Health Effects of Expansions in Health Expenditure in Indonesia: A Dynamic Panel Data Approach.
    Moler-Zapata S; Kreif N; Ochalek J; Mirelman AJ; Nadjib M; Suhrcke M
    Appl Health Econ Health Policy; 2022 Nov; 20(6):881-891. PubMed ID: 35997895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.